Finally, in an analysis of current clinical trials by Davoodi-Moghaddam et al., 68% of current phase III and IV trials of PI3K pathway inhibitors are in solid tumors with RCC and breast cancers being the most prevalent, and lymphoma is the most focused hematological malignancy being investigated. This evidence concerns the gene PIK3CG and breast carcinoma.